About
ResCure Pharma is developing novel platform technology for discovery and development of therapies for breast cancer recurrence. Approximately 20% of breast cancer patients are at risk of breast cancer recurrence 5-20 years after initial treatment. Recurrence can occur locally (in the treated breast or near the mastectomy scar) or appear as a metastatic disease in distant organs. To date there is no treatment to eradicate metastatic disease. Therefore, it is essential to develop new therapeutic approaches to confront metastatic disease before it emerges. ResCure is in the process of initial validation of potential compounds discovered by the company for the prevention and treatment of metastatic breast cancer recurrence.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is ResCure Pharma's primary focus?
- ResCure Pharma is developing novel platform technology for the discovery and development of therapies to prevent breast cancer recurrence.
- When was ResCure Pharma founded?
- ResCure Pharma was founded in March 2015.
- What is the current operational status of ResCure Pharma?
- ResCure Pharma has been inactive since August 2018.
- Where is ResCure Pharma headquartered?
- ResCure Pharma is headquartered in Haifa, Israel.
- What is ResCure Pharma's current funding stage?
- ResCure Pharma is currently in the Pre-Funding stage.
- What is the employee count for ResCure Pharma?
- ResCure Pharma has 6 employees.
- What is the total amount of funding raised by ResCure Pharma?
- ResCure Pharma has not raised any funding, with a total raised amount of $0 USD.
- What is the product stage of ResCure Pharma's technology?
- ResCure Pharma's technology is in the R&D product stage.
- Who is a co-founder of ResCure Pharma?
- Dalit Barkan is a co-founder of ResCure Pharma.